LMZ(SH:600249)2026-03-26 13:35Financial Performance - The company's operating revenue for 2025 reached ¥1,062,576,709.88, a year-on-year increase of 0.90% compared to ¥1,053,051,877.62 in 2024[23] - The total profit for 2025 was ¥10,561,161.28, reflecting a significant decrease of 90.44% from ¥110,447,055.93 in 2024[23] - The net profit attributable to shareholders for 2025 was ¥9,846,147.90, down 87.86% from ¥81,098,815.85 in 2024[23] - Basic earnings per share for 2025 were ¥0.0179, a decline of 87.86% from ¥0.1475 in 2024[24] - The weighted average return on equity for 2025 was 0.45%, down 3.30 percentage points from 3.75% in 2024[24] Cash Flow and Assets - The net cash flow from operating activities increased by 327.26% to ¥61,011,949.22 in 2025, compared to ¥14,279,946.49 in 2024[23] - The company's total assets as of the end of 2025 were ¥2,723,561,869.40, a slight increase of 0.10% from ¥2,720,923,571.60 in 2024[23] - The net assets attributable to shareholders at the end of 2025 were ¥2,177,795,295.97, a decrease of 0.30% from ¥2,184,449,148.07 in 2024[23] Revenue Breakdown - The company achieved a total operating revenue of 1.063 billion RMB in 2025, representing a year-on-year growth of 0.90%[34] - The net profit attributable to shareholders of the listed company was 9.8461 million RMB, while the net profit after deducting non-recurring gains and losses was 4.2798 million RMB, indicating a decline primarily due to the decrease in fair value changes of trading financial assets[35] - Domestic sales revenue decreased by 1.59% to CNY 981.48 million, while international sales revenue increased by 54.53% to CNY 66.73 million[51] - The company reported a revenue of approximately RMB 932.78 million in the daily chemical segment, with a gross profit margin of 13.45%[91] Research and Development - R&D expenses increased by 10.24% to CNY 19.10 million, reflecting the company's commitment to innovation and technology advancement[47] - The number of R&D personnel was 133, making up 8.06% of the total workforce[62] - The company is focusing on R&D in new raw material development and optimization of traditional Chinese medicine extraction processes[82] - The company completed a total of 68 new product registrations in 2025, including 40 toothpaste and 28 cosmetic products[81] Market and Competitive Landscape - The oral care industry is experiencing steady growth driven by rising disposable income and increased consumer awareness of oral health, with a notable shift towards personalized and deep care products[73] - The competitive landscape in the oral care market is shifting, with domestic brands gaining market share against international competitors through targeted innovation and marketing strategies[73] - The company faces intensified market competition in the daily chemical industry, requiring a focus on R&D, quality, and brand advantages to improve market competitiveness[109] Governance and Management - The board of directors held 9 meetings in 2025, with the audit committee meeting 8 times and the nomination committee meeting 3 times[116] - The company has established a stakeholder management approach to balance the interests of shareholders, employees, and society[119] - The company has a clear governance structure, with committees established to enhance the board's professional functions[116] - The company has appointed several new independent directors to strengthen its governance and oversight capabilities[126] Dividend Policy - The company plans to distribute a cash dividend of ¥0.30 per 10 shares, totaling ¥16,500,000.00, based on a total share capital of 550,000,000 shares[6] - The cash dividend distribution represents 167.58% of the net profit attributable to ordinary shareholders in the consolidated financial statements, which was CNY 9,846.15 million[152] - The company’s cash dividend policy prioritizes cash distributions, with a minimum of 10% of the distributable profit to be allocated as cash dividends[147] Social Responsibility - The company reported a total investment of CNY 31.91 million in social responsibility initiatives, benefiting 7,476 individuals[160] - The company invested CNY 51.39 million in poverty alleviation and rural revitalization projects, benefiting 253 individuals[162] - The company actively participated in volunteer services and community support, receiving recognition as a "2025 Annual Public Welfare Strategic Partner" from the China Oral Care Products Industry Association[161] Risks and Compliance - The company is exposed to risks from fluctuations in raw material prices, which could adversely affect procurement costs and gross margins[109] - The company has maintained compliance with accounting policies and has not reported any significant accounting errors[170] - The company has not faced significant differences in governance practices compared to regulatory requirements[121] Shareholder Information - The total number of ordinary shareholders as of the end of the reporting period is 40,276, an increase from 38,590 at the end of the previous month[183] - The largest shareholder, Guangxi Liuzhou Industrial Investment Development Group Co., Ltd., holds 183,360,652 shares, accounting for 33.34% of total shares[185] - The actual controller of the company is the Liuzhou Municipal Government State-owned Assets Supervision and Administration Commission[189]